Literature DB >> 10737728

Hemopexin as a carrier protein of tumor-localizing Ga-metalloporphyrin-ATN-2.

S Nakajima1, T Moriyama, H Hayashi, I Sakata, Y Nakae, T Takemura.   

Abstract

During size exclusion HPLC, ATN-2 binding protein separated from human and mouse sera, SCCVII and colon 26 tumor tissues were found in fraction 13 (A: estimated molecular weight 70,000). Fraction 13(A) of human sera was exclusively reactive to the human hemopexin antibody. During two-dimensional electrophoresis and amino acid sequence analysis, Fraction 13(A) of C3H/He mouse sera was found to have partial homology with the mouse hemopexin precursor. Glycoprotein with the same domain structure of hemopexin has been proposed to be an important carrier protein that forms the tumor-localizing activity of water-soluble porphyrin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737728     DOI: 10.1016/s0304-3835(99)00367-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Cell-cycle-dependent efficacy of photodynamic therapy with ATX-S10(Na).

Authors:  Munetaka Sano; Takahisa Furuta; Kenichiro Takahira; Masayoshi Kajimura; Hiroyuki Hanai; Eiji Kohno; Toru Hirano; Akira Hishida
Journal:  Lasers Med Sci       Date:  2005-05-24       Impact factor: 3.161

Review 2.  Porphyrins as ligands for 64copper: background and trends.

Authors:  Edgar Aguilar-Ortíz; Amir R Jalilian; Miguel A Ávila-Rodríguez
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

3.  Rhenium-188 labelled meso-tetrakis[3,4-bis(carboxymethyleneoxy)phenyl] porphyrin for targeted radiotherapy: preliminary biological evaluation in mice.

Authors:  Zhi-yun Jia; Hou-fu Deng; Man-fei Pu; Shun-zhong Luo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

4.  Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice.

Authors:  Y Takehara; H Sakahara; H Masunaga; S Isogai; N Kodaira; H Takeda; T Saga; S Nakajima; I Sakata
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.